Reducing BCL11A expression has been shown to alleviate symptoms in individuals with hemoglobin disorders via reactivation of HbF expression.110,111 However, only the genetic approaches clustered regularly interspaced short palindromic repeats (CRISPR) – Cas9 and RNA interference are used in patients.112 The sustained BCL11A degradation observed upon protein-based PROTAC treatment in HUDEP-2 cells prompted an investigation into the effect of ZF5.3-2D9-tSPOP on HbF induction in differenced HUDEP-2 and primary human hematopoietic stem cells (CD34+ cells). Here, BCL11A is linked to hemoglobinopathy.